Contract research organization Quintiles made its return to the market last week with a nearly $950 million IPO. The largest  CRO was acquired by a private equity syndicate that included Bain Capital back in 2008.

The private equity firms made a strong return on their purchase, but should investors jump in post IPO? In this video, health-care analyst David Williamson weighs the increasing importance of CROs like Quintiles with some of the less attractive aspects of the business.